Goldman Sachs upgrades Vir Biotechnology, says shares can more than double post-Covid

Indonesia Berita Berita

Goldman Sachs upgrades Vir Biotechnology, says shares can more than double post-Covid
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 CNBC
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 72%

The firm said the immunology company will release new flu vaccine data in the year ahead that could drive growth for the biotech stock.

Vir Biotechnology shares can more than double going forward, according to Goldman Sachs. Analyst Paul Choi upgraded the stock to buy from neutral, and raised his price target, saying the immunology company will release new flu vaccine data in the year ahead that could drive growth for the biotech stock. Called VIR-2482, the antibody treatment offers users broad protection against flu strains that could last the entirety of a flu season, according to Vir.

The biotech stock did well during the pandemic as it developed Covid treatments ; it more than doubled in 2020, and surged more than 50% in 2021. Then, in 2022, it tumbled near 40%. In 2023, the biotech stock is slightly higher, up 1.7%, still underperforming the S & P 500. Still, the analyst expects that shares can surge this year on a post-Covid story, rising more than 105% to the analyst's 12-month price target of $53. The price target was raised from $41.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

CNBC /  🏆 12. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Goldman names 2 global stocks to play the 'clean hydrogen revolution,' giving one 50% upsideGoldman names 2 global stocks to play the 'clean hydrogen revolution,' giving one 50% upsideGoldman Sachs says the 'clean hydrogen revolution' is here. It reveals two of its buy-rated stocks to play the boom.
Baca lebih lajut »

Reopening to recovery: Goldman Sachs sees China stocks surging as much as 24% by end of 2023Reopening to recovery: Goldman Sachs sees China stocks surging as much as 24% by end of 2023Goldman Sachs strategists see an economic shift from 'reopening to recovery' driving Chinese stocks 24% higher by the end of this year.
Baca lebih lajut »

'Insure against the worst': Goldman picks stocks for a soft — and hard — economic landing'Insure against the worst': Goldman picks stocks for a soft — and hard — economic landing'Expect the best (soft-landing) but insure against the worst (hard-landing),' Goldman Sachs said, naming its top stocks for both scenarios.
Baca lebih lajut »

Inspired by Kevin Love, on World Mental Health Day I share my storyInspired by Kevin Love, on World Mental Health Day I share my storyKevin Love has impacted the lives of millions through his mental health advocacy, including one of our own.
Baca lebih lajut »

Movers and shakers share weird tricks that helps them succeedMovers and shakers share weird tricks that helps them succeedWhen it works, it works. Such is the ethos of bigwigs in NYC and beyond who swear by a variety of oddball tricks to give them a leg up in their careers.
Baca lebih lajut »



Render Time: 2025-03-13 08:16:02